Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis.
about
Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells.Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndromeAntineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicityPalmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacyThe pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies.Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1 randomized trials.Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential.Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.The Clinical Significance of Endocannabinoids in Endometriosis Pain Management.Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patientsAdvances in the Physiology of GPR55 in the Central Nervous System.Palmitoylethanolamide in the Treatment of Failed Back Surgery SyndromePalmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease.The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms.Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect.
P2860
Q24630453-2A4B8B45-3800-428E-BAC0-2CFBA0583FD7Q26775847-56A78C8C-8B24-437B-8862-BEFA91212AE1Q27305830-092DD4CF-D6A9-40BF-B86D-998553D9333AQ28066248-6715FF01-0CCE-428D-8767-7FFCB36FDDAEQ31122398-4A68DD6F-9B02-487F-94C9-2C7E1BE662DAQ36365821-5FBD62EA-BE34-480D-BEF4-8143813ACCBFQ37138714-60696337-67B2-4855-A170-060A976426C3Q37675145-860D3FCB-E315-4A62-B881-C8EBD01BB9A6Q38157791-48EA103C-6ED6-45CC-A613-2A763922F6CAQ38598498-BAA8B4FD-337E-450A-BF5B-AEE34820DF00Q38908402-371E1F77-C724-445A-8098-2626BB9D6DA0Q38917434-356E7B61-320A-48F4-9E4D-78F2F18FD70DQ41508796-53970D11-F124-41CC-9171-9D106CDF1C1FQ42580206-10CE250C-E54D-4D90-B94B-2E8D83AF958AQ47127221-84E4615C-B909-41DA-B2CB-F97E404938B8Q52608759-BFEF947F-95E8-4271-B199-42E92FBEF396
P2860
Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Palmitoylethanolamide in the t ...... by different etiopathogenesis.
@ast
Palmitoylethanolamide in the t ...... by different etiopathogenesis.
@en
Palmitoylethanolamide in the t ...... by different etiopathogenesis.
@nl
type
label
Palmitoylethanolamide in the t ...... by different etiopathogenesis.
@ast
Palmitoylethanolamide in the t ...... by different etiopathogenesis.
@en
Palmitoylethanolamide in the t ...... by different etiopathogenesis.
@nl
prefLabel
Palmitoylethanolamide in the t ...... by different etiopathogenesis.
@ast
Palmitoylethanolamide in the t ...... by different etiopathogenesis.
@en
Palmitoylethanolamide in the t ...... by different etiopathogenesis.
@nl
P2093
P2860
P1433
P1476
Palmitoylethanolamide in the t ...... by different etiopathogenesis.
@en
P2093
Alessandro Fabrizio Sabato
Annarita Di Paolo
Antonio Gatti
Elisabetta Sabato
Marzia Lazzari
Valentina Gianfelice
P2860
P304
P356
10.1111/J.1526-4637.2012.01432.X
P577
2012-07-30T00:00:00Z